Orphan Drug Accelerator Spin-Out Tackles Rare Endocrine Disorders

15:59
 
Share
 

Manage episode 225199009 series 60790
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Tiburio Therapeutics emerged from the orphan drug accelerator Cydan at the start of 2019. The company is developing two clinical stage compounds for rare endocrine disorders that it licensed from Ipsen. We spoke to Tiburio Therapeutics CEO Abraham Ceesay, about rare endocrine disorders, the company’s pipeline, and the case for Cydan’s business model.

240 episodes available. A new episode about every 0 hours averaging 23 mins duration .